Sign in with Google. Opens in new tab
bullish
SK Bioscience (302440 KS): Flu Vaccine Output Resumes; Next-Gen Typhoid Vaccine Is On Card
541 Views14 Sep 2023 11:42
SUMMARY
- SK Bioscience (302440 KS) resumed flu vaccine shipment for 2023–24 flu season. The company temporarily stopped the production of flu vaccine to focus on the supply of COVID-19 vaccine.
- In August 2023, SK Bioscience has entered joint development agreement with Australia-based privately held biotechnology company Vaxxas to develop a second-generation needle-free patch delivery of typhoid conjugate vaccine.
- The company’s successful phase 2 clinical trial for first-in-class pneumococcal conjugate vaccine (PCV20+) in pediatric market is a step toward entry to the premium vaccine market.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- SK Bioscience (302440 KS): Operating Loss Widened in 3Q; What Lies Ahead26 Oct 2024
- SK Bioscience (302440 KS): Acquiring Majority Stake in IDT Biologika- A Step Toward ‘Globalization’29 Jun 2024
- SK Bioscience (302440 KS): Significantly Improved 3Q Result Benefitted From One-Time Payment28 Oct 2023
- SK Bioscience (302440 KS): Core Vaccines Gaining Traction; COVID Vaccine Gets International Approval13 Jun 2023
- SK Bioscience (302440 KS): Disappointing 2022 Result; Non-COVID Vaccines Are Key to Revival05 Mar 2023
- SK Bioscience (302440 KS): Murky Outlook On Weak Vaccine Demand And Flooding Supply06 Sep 2022
x